Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [615]

GU Debates 2019: Changing treatment paradigms for hormone-naïve and castration...

Dr Eleni Efstathiou, Prof Peter Goebell, Prof Joaquim Bellmunt, Prof Thomas...

GU Debates 2019: Changing treatment paradigms for hormone-naïve and castration-resistant prostate cancer (1/2) ( Dr Eleni Efstathiou, Prof Peter Goebell, Prof Joaquim Bellmunt, Prof Thomas Steuber )

GU Debates 2019: Practice-changing developments in urothelial cancer (2/2)

GU Debates 2019: Practice-changing developments in urothelial cancer (2/2) ( )

Gynaecological cancer: Where are we now?

Dr Nelleke Ottevanger - Radboud University Medical Center, Nijmegen, Netherlands

Gynaecological cancer: Where are we now? ( Dr Nelleke Ottevanger - Radboud University Medical Center, Nijmegen, Netherlands )

ASCO GU 2019: Treatment and management of hormone-sensitive metastatic prostate...

Prof Karim Fizazi, Dr Eleni Efstathiou

ASCO GU 2019: Treatment and management of hormone-sensitive metastatic prostate cancer ( Prof Karim Fizazi, Dr Eleni Efstathiou )

CB-839 in combination with cabozantinib in patients with clear cell and...

Prof Funda Meric-Bernstam - MD Anderson Cancer Center, Houston, USA

CB-839 in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer ( Prof Funda Meric-Bernstam - MD Anderson Cancer Center, Houston, USA )

ASCO GU 2019: Updates on treatment and management of bladder cancer

Professor Matthew Galsky, Professor Ananya Choudhury, Professor Joaquim...

ASCO GU 2019: Updates on treatment and management of bladder cancer ( Professor Matthew Galsky, Professor Ananya Choudhury, Professor Joaquim Bellmunt, Dr Andrea Necchi )

ASCO GU 2019: Updates on non-metastatic castration-resistant prostate cancer

Prof Karim Fizazi, Dr Eleni Efstathiou, Prof Boris Hadaschik, Prof Nicholas...

ASCO GU 2019: Updates on non-metastatic castration-resistant prostate cancer ( Prof Karim Fizazi, Dr Eleni Efstathiou, Prof Boris Hadaschik, Prof Nicholas Mottet )

Updates on metastatic bladder cancer from ASCO GU 2019

Prof Arlene Siefker-Radtke - MD Anderson Cancer Center, Houston, USA

Updates on metastatic bladder cancer from ASCO GU 2019 ( Prof Arlene Siefker-Radtke - MD Anderson Cancer Center, Houston, USA )

ASCO GU 2019 renal highlights

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

ASCO GU 2019 renal highlights ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC

Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA

ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC ( Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA )

CHEIRON study: Docetaxel plus enzalutamide versus docetaxel as first-line...

Dr Orazio Caffo - Santa Chiara Hospital, Trento, Italy

CHEIRON study: Docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patients with mCRPC ( Dr Orazio Caffo - Santa Chiara Hospital, Trento, Italy )

BGICC 2019 ( )

More from ecancer